Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
- PMID: 26198719
- PMCID: PMC7107395
- DOI: 10.1093/infdis/jiv392
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe disease in human with an overall case-fatality rate of >35%. Effective antivirals are crucial for improving the clinical outcome of MERS. Although a number of repurposed drugs, convalescent-phase plasma, antiviral peptides, and neutralizing antibodies exhibit anti-MERS-CoV activity in vitro, most are not readily available or have not been evaluated in nonhuman primates. We assessed 3 repurposed drugs with potent in vitro anti-MERS-CoV activity (mycophenolate mofetil [MMF], lopinavir/ritonavir, and interferon-β1b) in common marmosets with severe disease resembling MERS in humans. The lopinavir/ritonavir-treated and interferon-β1b-treated animals had better outcome than the untreated animals, with improved clinical (mean clinical scores ↓50.9%-95.0% and ↓weight loss than the untreated animals), radiological (minimal pulmonary infiltrates), and pathological (mild bronchointerstitial pneumonia) findings, and lower mean viral loads in necropsied lung (↓0.59-1.06 log10 copies/glyceraldehyde 3-phosphate dehydrogenase [GAPDH]; P < .050) and extrapulmonary (↓0.11-1.29 log10 copies/GAPDH; P < .050 in kidney) tissues. In contrast, all MMF-treated animals developed severe and/or fatal disease with higher mean viral loads (↑0.15-0.54 log10 copies/GAPDH) than the untreated animals. The mortality rate at 36 hours postinoculation was 67% (untreated and MMF-treated) versus 0-33% (lopinavir/ritonavir-treated and interferon-β1b-treated). Lopinavir/ritonavir and interferon-β1b alone or in combination should be evaluated in clinical trials. MMF alone may worsen MERS and should not be used.
Keywords: Kaletra; MERS; animal; common marmoset; coronavirus; interferon; lopinavir; mycophenolate; primate; treatment.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7107395/bin/jiv39201.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7107395/bin/jiv39202.gif)
![Figure 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7107395/bin/jiv39203.gif)
![Figure 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7107395/bin/jiv39204.gif)
![Figure 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7107395/bin/jiv39205.gif)
![Figure 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7107395/bin/jiv39206.gif)
Similar articles
-
Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets.Antiviral Res. 2018 Aug;156:64-71. doi: 10.1016/j.antiviral.2018.06.006. Epub 2018 Jun 7. Antiviral Res. 2018. PMID: 29885377 Free PMC article.
-
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.Trials. 2018 Jan 30;19(1):81. doi: 10.1186/s13063-017-2427-0. Trials. 2018. PMID: 29382391 Free PMC article.
-
A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.J Med Microbiol. 2017 Sep;66(9):1261-1274. doi: 10.1099/jmm.0.000565. Epub 2017 Aug 31. J Med Microbiol. 2017. PMID: 28855003 Free PMC article. Review.
-
A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection.Vet Pathol. 2016 May;53(3):521-31. doi: 10.1177/0300985815620845. Epub 2016 Feb 11. Vet Pathol. 2016. PMID: 26869154 Review.
-
Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.Antivir Ther. 2016;21(5):455-9. doi: 10.3851/IMP3002. Epub 2015 Oct 22. Antivir Ther. 2016. PMID: 26492219
Cited by
-
Harnessing the power of IFN for therapeutic approaches to COVID-19.J Virol. 2024 May 14;98(5):e0120423. doi: 10.1128/jvi.01204-23. Epub 2024 Apr 23. J Virol. 2024. PMID: 38651899 Review.
-
COVID-19 drug discovery and treatment options.Nat Rev Microbiol. 2024 Jul;22(7):391-407. doi: 10.1038/s41579-024-01036-y. Epub 2024 Apr 15. Nat Rev Microbiol. 2024. PMID: 38622352 Review.
-
[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].Med Intensiva. 2021 Mar;45(2):104-121. doi: 10.1016/j.medin.2020.06.017. Epub 2020 Jul 11. Med Intensiva. 2021. PMID: 38620757 Free PMC article. Spanish.
-
Marmosets as models of infectious diseases.Front Cell Infect Microbiol. 2024 Feb 23;14:1340017. doi: 10.3389/fcimb.2024.1340017. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38465237 Free PMC article. Review.
-
The Interrelationship between HIV Infection and COVID-19: A Review of the Literature.Curr HIV Res. 2024;22(1):6-15. doi: 10.2174/011570162X282739231222062830. Curr HIV Res. 2024. PMID: 38151836 Review.
References
-
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814–20. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials